« Back
Home /
GSK1059615

GSK1059615

Item no.	HY-12036-50mg
Manufacturer	MedChem Express
CASRN	958852-01-2
Amount	50 mg
Quantity options	100 mg 10mM/1mL 10 mg 50 mg 5 mg
Category	Oncology Inhibitors & Compound Libraries Small Molecules By Organ Breast Cancer
Type	Inhibitors
Clone	N/A
Specific against	other
Purity	99.0
Formula	C18H11N3O2S
Citations	[1]Carnero A. Novel inhibitors of the PI3K family. Expert Opin Investig Drugs. 2009 Sep;18(9):1265-77.<br/>[2]Maira SM, et al. From the bench to the bed side: PI3K pathway inhibitors in clinical development. Curr Top Microbiol Immunol, 2010, 347, 209-239.<br/>[3]Takashi Kei Kishimoto, et al. Methods and compositions for attenuating gene therapy anti-viral transfer vector immune responses. US 20160074531 A1.
Smiles	O=C(S/C1=C\C2=CC=C3N=CC=C(C3=C2)C4=CC=NC=C4)NC1=O
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	958852-01-2
Available
Product Description	GSK1059615 is a dual inhibitor of PI3Kα/β/δ/γ (reversible) and mTOR with IC50 of 0.4 nM/0.6 nM/2 nM/5 nM and 12 nM, respectively.
StorageTemperature	-20°C, 3 years; 4°C, 2 years (Powder)
Shipping	Room Temperature
Manufacturers Applications	Cancer-Kinase/protease
MolecularWeight	333.36
Clinical Information	Phase 1
Manufacturers Research Area	Cancer
Solubility	DMSO : 5 mg/mL (ultrasonic)
Target	Apoptosis; mTOR; PI3K
Manufacturers Target	Apoptosis; mTOR; PI3K
Isoform	mTOR; PI3Kα; PI3Kβ; PI3Kγ; PI3Kδ
Manufacturers Pathway	Apoptosis; PI3K/Akt/mTOR
Manufacturers Product type	Reference compound

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-12036-50mg-safety-datasheet.pdf